Predilife: Update on the FDA procedure and 2025 financial report

Predilife, a company specializing in artificial intelligence for personalized medicine, has released updates on its FDA application and published its 2025 financial report. Following the submission of Denseerisk, which combines AI imaging and Mammorisk, the FDA posed technical questions, which Predilife addressed promptly. A comparison with Clairity raised no doubts, which is encouraging, given that Clairity recently raised $43 million. Predilife's financial report is available online, but the accounts have not been audited due to financial uncertainties. The company is in receivership, and its continued operation depends on raising further funds and implementing a business continuity plan.